Traumatic Brain Injury Treatment Market size was valued at USD 3.03 billion in 2021. It is expected to reach a value of USD 5.26 billion by 2028, growing at a CAGR of 8.2% from 2022 to 2028. Traumatic brain injury (TBI) or intracranial injury is an injury to brain due to external force to brain. TBI can be classified as mild, moderate, and severe brain injury. TBI may be occur due to falls, vehicle collision, and violence. Symptoms of traumatic brain injury include cognitive, physical, social, and behavioural symptoms and outcome can range from complete recovery to permanent disability and may causes death. TBI can be diagnosed by using computed tomography (CT) and magnetic resonance imaging (MRIs). In May 2016, Stemedica Cell Technologies, Inc. received FDA investigational new drug (IND) approval for mesenchymal stem cells to treat traumatic brain injury. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. This market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.